GC
HQL

Guggenheim Capital’s abrdn Life Sciences Investors HQL Stock Holding History

Guggenheim Capital’s Portfolio HQL Stock Details HQL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$863K Buy
53,045
+11,978
+29% +$200K 0.01% 1033
2025
Q4 		$689K Buy
41,067
+14,582
+55% +$245K ﹤0.01% 1130
2025
Q3 		$411K Sell
26,485
-1,298
-5% -$17.8K ﹤0.01% 1262
2025
Q2 		$356K Sell
27,783
-569
-2% -$7.01K ﹤0.01% 1340
2025
Q1 		$360K Buy
28,352
+12,299
+77% +$167K ﹤0.01% 1349
2024
Q4 		$211K Buy
+16,053
New +$232K ﹤0.01% 1584
2024
Q3 		– Sell
-27,505
Closed -$390K – 1899
2024
Q2 		$390K Buy
27,505
+1,882
+7% +$25.5K ﹤0.01% 1543
2024
Q1 		$349K Sell
25,623
-3,564
-12% -$49.3K ﹤0.01% 1612
2023
Q4 		$393K Buy
29,187
+1,079
+4% +$13.3K ﹤0.01% 1553
2023
Q3 		$351K Buy
28,108
+112
+0.4% +$1.47K ﹤0.01% 1572
2023
Q2 		$379K Buy
27,996
+3,021
+12% +$41.7K ﹤0.01% 1574
2023
Q1 		$348K Buy
24,975
+14,241
+133% +$204K ﹤0.01% 1632
2022
Q4 		$153K Buy
+10,734
New +$156K ﹤0.01% 1839
2022
Q1 		– Sell
-10,792
Closed -$208K – 2151
2021
Q4 		$208K Sell
10,792
-11,759
-52% -$237K ﹤0.01% 2026
2021
Q3 		$469K Buy
22,551
+44
+0.2% +$942 ﹤0.01% 1763
2021
Q2 		$483K Sell
22,507
-1,760
-7% -$35.5K ﹤0.01% 1845
2021
Q1 		$479K Sell
24,267
-1,078
-4% -$22.2K ﹤0.01% 1732
2020
Q4 		$500K Sell
25,345
-115
-0.5% -$2.13K ﹤0.01% 1641
2020
Q3 		$447K Buy
25,460
+3,433
+16% +$61.5K ﹤0.01% 1485
2020
Q2 		$396K Sell
22,027
-8,682
-28% -$149K ﹤0.01% 1518
2020
Q1 		$460K Buy
30,709
+6,654
+28% +$109K ﹤0.01% 1389
2019
Q4 		$419K Buy
24,055
+7,370
+44% +$121K ﹤0.01% 1661
2019
Q3 		$252K Sell
16,685
-1,114
-6% -$17.8K ﹤0.01% 1924
2019
Q2 		$300K Sell
17,799
-87
-0.5% -$1.43K ﹤0.01% 1864
2019
Q1 		$306K Sell
17,886
-514
-3% -$8.87K ﹤0.01% 1890
2018
Q4 		$278K Buy
18,400
+4,155
+29% +$73.2K ﹤0.01% 1926
2018
Q3 		$291K Buy
+14,245
New +$283K ﹤0.01% 2220
2016
Q2 		– Sell
-20,664
Closed -$371K – 2899
2016
Q1 		$371K Sell
20,664
-2,306
-10% -$41.9K ﹤0.01% 2481
2015
Q4 		$543K Sell
22,970
-4,565
-17% -$113K ﹤0.01% 2412
2015
Q3 		$620K Sell
27,535
-4,298
-14% -$120K ﹤0.01% 2332
2015
Q2 		$898K Sell
31,833
-1,303
-4% -$36.1K ﹤0.01% 2275
2015
Q1 		$913K Sell
33,136
-806
-2% -$22K ﹤0.01% 2285
2014
Q4 		$844K Buy
33,942
+7,391
+28% +$177K ﹤0.01% 2304
2014
Q3 		$587K Buy
+26,551
New +$577K ﹤0.01% 2492

Other funds holding HQL

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
FHA
Flagship Harbor Advisors Boston, Massachusetts $2.27B AUM 18.34% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Guggenheim Capital's HQL Position: Q1 2026 in Review

Guggenheim Capital increased its abrdn Life Sciences Investors (HQL) stake by 29% in Q1 2026, buying an estimated $200K and bringing the position to 53,045 shares worth $863K. The position accounts for 0.01% of the portfolio, ranked #1033.

Guggenheim Capital first reported a position in HQL in Q3 2014 and has held it in 34 quarters since. The position peaked at $913K in Q1 2015. 86 funds tracked by Wall St. Rank hold HQL as of Q1 2026.

  • Guggenheim Capital held 53,045 shares of abrdn Life Sciences Investors worth $863K as of Q1 2026.
  • Guggenheim Capital bought 11,978 abrdn Life Sciences Investors shares in Q1 2026, an estimated $200K.
  • abrdn Life Sciences Investors made up 0.01% of Guggenheim Capital's portfolio in Q1 2026, its #1033 holding.
  • Guggenheim Capital first reported a position in abrdn Life Sciences Investors in Q3 2014 and has held it in 34 quarters since.
  • Guggenheim Capital's abrdn Life Sciences Investors position peaked at $913K in Q1 2015.
  • 86 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q1 2026.

Based on Guggenheim Capital's 13F filing for Q1 2026, filed 15 May 2026.